Moderate riskFDA DrugClass II

Reliance Life Sciences azacitidine recalled for sterility assurance

Reliance Life Sciences is recalling azacitidine for injection, 100 mg single-dose vials, manufactured for Somerset Therapeutics. The notice cites a lack of sterility assurance for 8,001 vials across 12 lots, distributed nationwide. No injuries have been reported.

From the FDA notice · Read the official notice ↗

What to do

  1. Set aside affected vials and do not administer them.
  2. Check NDC 70069-0857-01 and lots RAZM0425A through RAZM2025A (expiry June to September 2027) on vial cartons.
  3. The notice does not say how to get a replacement or refund; contact Somerset Therapeutics, LLC.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Azacitidine for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For Subcutaneous and Intravenous Use, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873 NDC: 70069-0857-01
Sold in
Nationwide
Made for
Adults (0 months and older)

This recall covers 4 products — see all of them.

Details

Units affected
8,001 vials
Illnesses reported
None reported
Manufactured in
Ttc Area Of Midc, R - 282 Dhirubhai Ambani Life Sciences Centre; Thane Belapur Road, Navi Mumbai, N/A, India
Classification
Class II
Recall number
D-0674-2026

In the FDA's words

Description
Azacitidine for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For Subcutaneous and Intravenous Use, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873 NDC: 70069-0857-01 Lack of Sterility Assurance Lot, expiry: RAZM0425A Jun 30, 2027; RAZM0525A Jun 30, 2027; RAZM0725A Jun 30, 2027; RAZM0825A Jun 30, 2027; RAZM0925A Jul 31, 2027; RAZM1125A Jul 31, 2027; RAZM1225A Jul 31, 2027; RAZM1425A Jul 31, 2027; RAZM1525A Jul 31, 2027; RAZM1625A Aug 31, 2027; RAZM1725A Aug 31, 2027; RAZM2025A Sep 30, 2027 Distribution: Nationwide in the USA Affected quantity: 8,001 vials
Hazard
Lack of Sterility Assurance

4 products in this recall

Somerset Therapeutics cancer drug vials recalled for lack of sterility

Reliance Life Sciences is recalling four injectable cancer drugs made for Somerset Therapeutics: Pemetrexed for Injection 100 mg and 500 mg vials, Bortezomib for Injection 3.5 mg vials, and Azacitidine for Injection 100 mg vials. The recall covers about 36,000 vials nationwide because of a lack of sterility assurance. No injuries have been reported.

The agency lists each product separately. Check every one you might have.

Related topics

SterilityDrugsSold nationwideMore from FDA Drug